Pitney Bowes Inc., operates as a technology-driven company that provides SaaS shipping solutions, mailing innovation, and financial services to small businesses, large enterprises, and government entities around the world. It operates through SendTech Solutions and Presort Services segments. The SendTech Solutions segment provides physical and digital shipping and mailing technology solutions, and other applications for sending, tracking and receiving of letters, parcels and flats, supplies, and maintenance services, as well as financing alternatives to finance equipment and product purchases. The Presort Services segment offers mail sortation services, which allow clients to qualify volumes of first-class mail, marketing mail, marketing mail flats, and bound printed matter for postal workshare discounts. It markets its products, solutions, and services through direct and inside sales force, global and regional partner channels, direct mailings, and digital channels. The company was formerly known as Pitney Bowes Postage Meter Company. Pitney Bowes Inc. was incorporated in 1920 and is headquartered in Stamford, Connecticut.

Pitney Bowes Inc.

The latest update is out from Paradigm Biopharmaceuticals ( ($AU:PAR) ). Paradigm Biopharmaceuticals has disclosed a change in the indirect interes...

Paradigm Biopharmaceuticals Updates Director Matthew Fry’s Option Holdings

An announcement from Paradigm Biopharmaceuticals ( ($AU:PAR) ) is now available. Paradigm Biopharmaceuticals has reported a change in the interests...

Paradigm Biopharmaceuticals updates market on director Paul Rennie’s expanded option holdings

Paradigm Biopharmaceuticals ( ($AU:PAR) ) just unveiled an announcement. Paradigm Biopharmaceuticals has applied for the quotation of 10,139,313 ne...

Paradigm Biopharmaceuticals Seeks ASX Quotation for Over 10 Million New Shares

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an announcement. Paradigm Biopharmaceuticals has released an updated top holders report for ...

Paradigm Biopharmaceuticals’ Top 20 Option Holders Control Majority of PAROPTWC Register

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an update. Paradigm Biopharmaceuticals has applied to the ASX for quotation of a new class of ...

Paradigm Biopharmaceuticals Seeks ASX Quotation for 117 Million New Options

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an update. Paradigm Biopharmaceuticals has disclosed a change in director Matthew Fry’s indire...

Paradigm Director Increases Stake via Share Purchase Plan

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an announcement. Paradigm Biopharmaceuticals has announced changes to the interests of direc...

Paradigm Director Paul Rennie Increases Stake Through Additional Share Purchases

The latest update is out from Paradigm Biopharmaceuticals ( ($AU:PAR) ). Paradigm Biopharmaceuticals Limited has announced the cessation of 1,352,8...

Paradigm Biopharmaceuticals Redeems Over 1.3 Million Convertible Notes

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an update. Paradigm Biopharmaceuticals has applied for quotation on the ASX of 7,657,720 new...

Paradigm Biopharmaceuticals Seeks Quotation for 7.7 Million New Shares on ASX

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an announcement. Paradigm Biopharmaceuticals has updated its disclosure to the ASX regarding...

Paradigm Biopharmaceuticals Corrects Share Purchase Plan Details in ASX Filing

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an announcement. Paradigm Biopharmaceuticals has completed an oversubscribed Share Purchase Pl...

Market Cap	$2.37B	P/E Ratio	10.80
52W High	$16.56	52W Low	$8.95
Div Yield	40.0%	Payout Ratio	31.4%
EPS Growth 3Y	58.7%	52W Position	112.4%
Overall Score	75	Value Score	80
Quality Score	55	Technical Score	91

EPS Current Est	$1.62	EPS Next Est	$1.76
EPS Growth Est	+8.6%	DPS Growth 3Y	0.0%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PBI	$17.50	+0.69%	8.01M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PBI	$17.50	+0.7%	8.01M
3
4
5
6

PBI

PBI

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Pitney Bowes Inc. Data in Excel

Get Pitney Bowes Inc. Data in Excel